Quince Therapeutics (NASDAQ:QNCX – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.09), Zacks reports. The firm had revenue of $0.17 million during the quarter.
Quince Therapeutics Trading Down 2.1 %
Shares of NASDAQ:QNCX opened at $1.37 on Wednesday. The business’s 50 day moving average price is $1.49 and its 200-day moving average price is $1.44. Quince Therapeutics has a 1 year low of $0.51 and a 1 year high of $2.45. The firm has a market capitalization of $60.28 million, a price-to-earnings ratio of -1.10 and a beta of 0.71. The company has a debt-to-equity ratio of 0.33, a current ratio of 9.53 and a quick ratio of 9.53.
Wall Street Analyst Weigh In
Several equities analysts have recently issued reports on QNCX shares. Oppenheimer initiated coverage on shares of Quince Therapeutics in a report on Monday. They set an “outperform” rating and a $10.00 price objective on the stock. D. Boral Capital dropped their target price on shares of Quince Therapeutics from $12.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Brookline Capital Management started coverage on shares of Quince Therapeutics in a report on Wednesday, December 18th. They issued a “buy” rating and a $9.00 price target for the company. Five investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Quince Therapeutics currently has a consensus rating of “Buy” and an average target price of $8.00.
About Quince Therapeutics
Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
Recommended Stories
- Five stocks we like better than Quince Therapeutics
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Healthy Energy Drinks? Celsius Holdings Building Out the Space
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Occidental’s Billion-Dollar Carbon Credit Plan Takes Shape
- Overbought Stocks Explained: Should You Trade Them?
- Airship AI: Why This AI Penny Stock Is Poised for a Big Breakout
Receive News & Ratings for Quince Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quince Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
